Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 1103-1110

  Jokinen, Elina ^a   Koivunen, Jussi P ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Drug resistance; MEK inhibition; PI3K inhibition; Solid malignancies; Targeted cancer therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; DASATINIB; ENTINOSTAT; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; MCL1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL X; PYRIDINE DERIVATIVE; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; IMMUNOPRECIPITATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; HCT116 CELL LINE; HUMAN; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DASATINIB; DRUG SYNERGISM; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; SULFONAMIDES;

EID: 84938071015     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3071     Document Type: Article

References (19)

1. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
2. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V , Grbovic-Huezo O, Serra V, Majumder PK, Baselga J and Rosen N: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19: 58-71, 2011.
3. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson R T, Lifshits E, Chen Z, Maira SM, García-Echeverría C, et al: Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106: 19503-19508, 2009.
4. Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36: 320-328, 2011.
5. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM and Engelman JA: MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72: 3228-3237, 2012.
6. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006.
7. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, et al: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72: 210-219, 2012.
8. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, et al: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 106: 18351-18356, 2009.
9. Jokinen E, Laurila N and Koivunen JP: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. BMC Cancer 12: 612, 2012.
10. Bedard P, Tabernero J, Kurzrock R, et al: A phase lb, openlabel, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol (ASC Annual Meeting abstracts) 30: 3003, 2012.
11. Britten C, Wainberg Z, Tabernero J, et al: A multi-arm phase 1 dose escalation study of safety, pharmacokinetics, and pharmacodynamics of the dual PI3K/mTOR inhibitors PF-04691502 (oral) and PF-05212384 (IV ) in combination with the MEK inhibitor PD-0325901 or irinotecan in patients with advanced cancer. Eur J Cancer 48: 109, 2012.
12. LoRusso P, Shapiro G, Pandya SS, et al: A first-in-human phase 1b study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol (ASC Annual Meeting abstracts) 30: 2566, 2012.
13. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, et al: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 4: 42-52, 2014.
14. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, et al: Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res 74: 3146-3156, 2014.
15. Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
16. Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, et al: Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res 18: 1051-1062, 2012.
17. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C and Stegmeier F: PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293, 2009.
18. Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G , Godoy A and Pili R: Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget 4: 2225-2236, 2013.
19. He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH and Ellisen LW: Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov 3: 324-337, 2013.